<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377478</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19030435</org_study_id>
    <nct_id>NCT03377478</nct_id>
  </id_info>
  <brief_title>Expanding the Pool in Lung Transplantation</brief_title>
  <official_title>Expanding the Pool in Lung Transplantation: The Use of Hepatitis C Positive Donor Lungs in Hepatitis C Negative Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pablo Sanchez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To perform a study (20 patients) utilizing Hepatitis C positive (HCV Ab+/NAT -) donor lungs&#xD;
      for hepatitis C negative recipients with post-operative surveillance and treatment only if a&#xD;
      recipient infection occurs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are proposing a study of efficacy, in which positive donors will be used&#xD;
      for HCV negative patients. Following lung transplantation patients will undergo HCV antibody,&#xD;
      virus PCR, and liver function testing. Recipients whom test positive for HCV viremia for 2&#xD;
      consecutive tests at any point will complete 12 weeks of Sofosbuvir/velpatasvir therapy.&#xD;
&#xD;
      This initial study would enroll 20 patients and utilize donors that are young, otherwise&#xD;
      healthy whom are Hepatitis C antibody positive but Nucleic Acid Amplification Testing (NAT)&#xD;
      negative (HCV Ab+/NAT-). The recipients would be limited to those patients who have&#xD;
      previously consented to receive a high risk lung transplant, consented to participant in this&#xD;
      study, and who are physiologically optimized for transplantation (e.g., low risk for lung&#xD;
      transplantation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2026</completion_date>
  <primary_completion_date type="Actual">September 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV Viremia</measure>
    <time_frame>at 2 years</time_frame>
    <description>Incidence of HCV Viremia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>at 2 years</time_frame>
    <description>Rate of HCV seroconversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Function Testing</measure>
    <time_frame>at 2 years</time_frame>
    <description>Assessment of Hepatic function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>at 2 years</time_frame>
    <description>Survival rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rejection</measure>
    <time_frame>at 2 years</time_frame>
    <description>The incidence of rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waitlist</measure>
    <time_frame>at 2 years</time_frame>
    <description>Time on waitlist will be assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Lung Transplant</condition>
  <arm_group>
    <arm_group_label>Lung Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be transplanted with HCV positive lung. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epclusa</intervention_name>
    <description>Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.</description>
    <arm_group_label>Lung Transplant</arm_group_label>
    <other_name>Procedure</other_name>
    <other_name>Sofosbuvir/velpatasvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who sign the informed consent for this study&#xD;
&#xD;
          -  Patients whom agree to receive a PHS high risk organ&#xD;
&#xD;
          -  Patients listed for heart transplantation&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not sign informed consent for this study&#xD;
&#xD;
          -  HIV Seropositivity&#xD;
&#xD;
          -  HBV Seropositivity (HBcAb and/or HBsAg positive)&#xD;
&#xD;
          -  Abnormal liver enzymes - 3 times the normal liver function values (Bilirubin, INR,&#xD;
             AST, ALT)&#xD;
&#xD;
          -  Acute or chronic renal insufficiency (creatinine clearance &lt;50 ml/min) or history of&#xD;
             dialysis&#xD;
&#xD;
          -  Patients on ECMO&#xD;
&#xD;
          -  Respiratory insufficiency requiring mechanical respiratory support (ventilator, BiPAP)&#xD;
&#xD;
          -  Liver insufficiency&#xD;
&#xD;
          -  Prior history of hepatitis C&#xD;
&#xD;
          -  Allergy to Sofosbuvir/velpatasvir&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Surgery/University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://druginfo.nlm.nih.gov/drugportal/name/Sofosbuvir</url>
    <description>Sofosbuvir</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>Drug Information</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Pablo Sanchez</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

